FIZZ heads into its September 8 earnings print with the sole analyst covering it firmly in the bear camp, and the stock trading just cents above where that analyst thinks it belongs.
UBS has maintained a Sell rating on National Beverage Corp. throughout 2026, lowering its target to $32 on September 4 — from $33 previously — leaving virtually no gap between the target and the current price of $32.24. The direction of travel is clear: UBS has cut its target six times since late 2025, taking it from $45 down to $32 in roughly a year. The bull case for FIZZ rests on the LaCroix brand's continued sparkling-water category positioning and the company's lean cost structure, but the bear argument — embodied by UBS's persistent Sell — centres on stretched valuation and a lack of volume catalysts to justify the multiple. The PE multiple near 26x and EV/EBITDA around 18x are not cheap for a company with a single dominant brand and no meaningful near-term earnings growth catalyst on the horizon.
Options traders are actually leaning more optimistic than usual into the report. The put/call ratio has dropped to 0.31, roughly 1.3 standard deviations below its 20-day average of 0.37. Calls are clearly the preferred instrument heading into the print — a contrast with the caution visible on the analyst side. Short interest, at around 4.8% of the free float, has climbed about 21% over the past month, though the borrow market remains wide open: availability is deep at nearly 779% of short interest, and the cost to borrow is negligible at 0.50%. The lending market is not signalling any kind of squeeze pressure. The ORTEX short score, near 64.5, reflects the building short interest trend but sits well short of extreme territory.
Ownership adds a layer of context worth noting. IBS Partners holds over 71% of shares — an extraordinarily concentrated structure that effectively removes most of the float from active trading. Nick and Joseph Caporella together account for another 3% as named holders. The one recent insider move was a director buying just 250 shares at $31.78 in July — a token purchase of roughly $8,000 rather than a conviction signal. The company's most notable recent shareholder-friendly action was the $3.25 special cash dividend declared in early July, a pattern it has deployed periodically but inconsistently over the years.
Past earnings reactions have been uniformly positive: the last four prints each produced a gain on the day, with moves ranging from 1.5% to 6.8%, and five-day returns stayed positive in three of those four cases. The September 8 print will test whether that string continues at a price level that has now converged almost exactly with UBS's Sell target — leaving the stock little analytical cushion if the quarter disappoints.
See the live data behind this article on ORTEX.
Open FIZZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
